The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADAMAS PHARMACEUTICALS INC | COM | 00548A106 | 1,940 | 757,704 | SH | SOLE | 757,704 | 0 | 0 | ||
| APOLLO ENDOSURGERY INC | COM | 03767D108 | 2,367 | 1,447,765 | SH | SOLE | 1,447,765 | 0 | 0 | ||
| BRICKELL BIOTECH INC | COM | 10802T105 | 147 | 146,739 | SH | SOLE | 146,739 | 0 | 0 | ||
| CATALYST BIOSCIENCES INC | COM NEW | 14888D208 | 3,214 | 547,541 | SH | SOLE | 547,541 | 0 | 0 | ||
| CERECOR INC | COM | 15671L109 | 1,171 | 450,500 | SH | SOLE | 450,500 | 0 | 0 | ||
| CUMBERLAND PHARMACEUTICALS | COM | 230770109 | 2,253 | 676,592 | SH | SOLE | 676,592 | 0 | 0 | ||
| CTI BIOPHARMA CORP | COM | 12648L601 | 4,719 | 4,068,191 | SH | SOLE | 4,068,191 | 0 | 0 | ||
| DIAMEDICA THERAPEUTICS INC | COM NEW | 25253X207 | 4,632 | 668,430 | SH | SOLE | 668,430 | 0 | 0 | ||
| IVERIC BIO INC | COM | 46583P102 | 13,972 | 2,739,641 | SH | SOLE | 2,739,641 | 0 | 0 | ||
| LIGAND PHARMACEUTICALS | COM NEW | 53220K504 | 10,336 | 92,407 | SH | SOLE | 92,407 | 0 | 0 | ||
| NEOS THERAPEUTICS INC | COM | 64052L106 | 3,046 | 4,447,026 | SH | SOLE | 4,447,026 | 0 | 0 | ||
| PROGENITY INC | COM | 74319F107 | 865 | 96,135 | SH | SOLE | 96,135 | 0 | 0 | ||
| XOMA CORP | COM NEW | 98419J206 | 2,968 | 150,213 | SH | SOLE | 150,213 | 0 | 0 | ||